Harvard Bioscience (HBIO) Tops Q2 EPS by 24c ; Offers Guidance

Harvard Bioscience (NASDAQ: HBIO) reported Q2 EPS of ($0.14), $0.24 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $22.73 million versus the consensus estimate of $21.9 million.

Q3 2026 Outlook:-

Revenue between $21.0 million and $22.6 million vs consensus $21.85 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Trinity Biotech faces Nasdaq delisting risk over market value
• Zentek shares to move from Nasdaq to OTC Markets on Sept. 2